Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | GMPS | P49915 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 2/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | AHCY | P23526 | 2/20 | 0.35 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646291 | 0.88 | ADORA2A (0.56) | ADORA3ADORA2ASLC28A1PRMT5WDR77 | |
| SCHEMBL30612765 | 0.85 | ADORA3 (0.39) | ADORA3ADORA2ASLC28A1PRMT5WDR77 | |
| SCHEMBL30612745 | 0.81 | GMPS (0.37) | ADORA3ADORA2ASLC28A1PRMT5WDR77 | |
| SCHEMBL30382315 | 0.75 | ADORA2A (0.52) | ADORA3ADORA2ASLC28A1PRMT5WDR77 | |
| SCHEMBL8108646 | 0.75 | ADORA2A (0.36) | ADORA3ADORA2ASLC28A1PRMT5WDR77 | |
| SCHEMBL28171063 | 0.74 | ADORA2A (0.51) | ADORA3ADORA2ASLC28A1PRMT5WDR77 | |
| SCHEMBL20833563 | 0.74 | ADORA2A (0.51) | ADORA3ADORA2ASLC28A1PRMT5WDR77 | |
| SCHEMBL28171639 | 0.74 | ADORA2A (0.54) | ADORA3ADORA2ASLC28A1PRMT5WDR77 | |
| SCHEMBL646779 | 0.74 | ADORA3 (0.47) | ADORA3HIF1A | |
| SCHEMBL9851782 | 0.73 | PI4KA (0.31) | ADORA3ADORA2ASLC28A1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009517350-A | — | — | 2009-04-30 | — | — | JP | claimed |
| US-20090017106-A1 | ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTENE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2009-01-15 | — | — | US | claimed |
| EP-1973571-A1 | NEW ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTEINE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2008-10-01 | — | — | EP | claimed |
| WO-2007059931-A1 | NEW ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTEINE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2007-05-31 | — | — | WO | claimed |
| US-8119689-B2 | Adjuvants on the basis of bisacyloxypropylcystene conjugates and derivatives and their uses in pharmaceutical compositions | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20090017106-A1 | ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTENE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2009-01-15 | — | — | US | disclosed |
| EP-1973571-A1 | NEW ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTEINE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007059931-A1 | NEW ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTEINE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090017106-A1 | ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTENE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | CYSLTR2, CYSLTR1, GSTO1 | ADORA3 941/4885ADORA2A 724/4885SLC28A1 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.